AUTHOR=Zhang Ting , Liu Xu , Zhang Lu , Jiang Xian TITLE=Treatment of rosacea with upadacitinib and abrocitinib: case report and review of evidence for Janus kinase inhibition in rosacea JOURNAL=Frontiers in Immunology VOLUME=Volume 15 - 2024 YEAR=2024 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1416004 DOI=10.3389/fimmu.2024.1416004 ISSN=1664-3224 ABSTRACT=Introduction: Conventional rosacea treatments are not uniformly pervasive, and the adverse reactions can potentially constrain their utility. The clinical use of JAK1 inhibitor upadacitinib and abrocitinib in the treatment of refractory rosacea have rarely been explored.We presented the two cases of patients who received JAK1 inhibitor upadacitinib and four cases of patients who received JAK1 inhibitor abrocitinib for the treatment of refractory rosacea.Discussion: JAK1 inhibitor upadacitinib and abrocitinib may be promising medical options for patients with refractory rosacea. However, the long-term safety and efficacy of upadacitinib and abrocitinib require prospective controlled studies to assess more comprehensively.